Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

DAPK1 Promoter Methylation and Cervical Cancer Risk: A Systematic Review and a Meta-Analysis.

Agodi A, Barchitta M, Quattrocchi A, Maugeri A, Vinciguerra M.

PLoS One. 2015 Aug 12;10(8):e0135078. doi: 10.1371/journal.pone.0135078. eCollection 2015. Review.

2.

Association between DAPK1 promoter methylation and cervical cancer: a meta-analysis.

Xiong J, Li Y, Huang K, Lu M, Shi H, Ma L, Luo A, Yang S, Lu Z, Zhang J, Yang L, Wang S.

PLoS One. 2014 Sep 30;9(9):e107272. doi: 10.1371/journal.pone.0107272. eCollection 2014.

3.

Correlation of DAPK1 methylation and the risk of gastrointestinal cancer: A systematic review and meta-analysis.

Yuan W, Chen J, Shu Y, Liu S, Wu L, Ji J, Liu Z, Tang Q, Zhou Z, Cheng Y, Jiang B, Shu X.

PLoS One. 2017 Sep 21;12(9):e0184959. doi: 10.1371/journal.pone.0184959. eCollection 2017. Review.

4.

DAPK1, MGMT and RARB promoter methylation as biomarkers for high-grade cervical lesions.

Sun Y, Li S, Shen K, Ye S, Cao D, Yang J.

Int J Clin Exp Pathol. 2015 Nov 1;8(11):14939-45. eCollection 2015.

5.

Promoter hypermethylation of CDH13, DAPK1 and TWIST1 genes in precancerous and cancerous lesions of the uterine cervix.

Missaoui N, Hmissa S, Trabelsi A, Traoré C, Mokni M, Dante R, Frappart L.

Pathol Res Pract. 2011 Jan 15;207(1):37-42. doi: 10.1016/j.prp.2010.11.001. Epub 2010 Dec 3.

PMID:
21129853
6.

[Promoter methylation of DAPK1, RAR-β and MGMT in exfoliated cervical cytology and its clinical application].

Zhong ZJ, Yang JX, Cao DY, Sun Y, Sun LL, Cheng XM, Chen J, Lang JH, Shen K.

Zhonghua Fu Chan Ke Za Zhi. 2012 Mar;47(3):196-200. Chinese.

PMID:
22781071
7.

Hypermethylation of Death-Associated Protein Kinase (DAPK1) and its association with oral carcinogenesis - An experimental and meta-analysis study.

Jayaprakash C, Varghese VK, Bellampalli R, Radhakrishnan R, Ray S, Kabekkodu SP, Satyamoorthy K.

Arch Oral Biol. 2017 Aug;80:117-129. doi: 10.1016/j.archoralbio.2017.03.024. Epub 2017 Mar 31.

PMID:
28412611
8.

DAPK Promoter Methylation and Bladder Cancer Risk: A Systematic Review and Meta-Analysis.

Dai L, Ma C, Zhang Z, Zeng S, Liu A, Tang S, Ren Q, Sun Y, Xu C.

PLoS One. 2016 Dec 1;11(12):e0167228. doi: 10.1371/journal.pone.0167228. eCollection 2016. Review.

9.

Identification of DAPK1 Promoter Hypermethylation as a Biomarker for Intra-Epithelial Lesion and Cervical Cancer: A Meta-Analysis of Published Studies, TCGA, and GEO Datasets.

Wang XB, Cui NH, Liu XN, Ma JF, Zhu QH, Guo SR, Zhao JW, Ming L.

Front Genet. 2018 Jul 17;9:258. doi: 10.3389/fgene.2018.00258. eCollection 2018.

10.

Detection of hypermethylated genes in women with and without cervical neoplasia.

Feng Q, Balasubramanian A, Hawes SE, Toure P, Sow PS, Dem A, Dembele B, Critchlow CW, Xi L, Lu H, McIntosh MW, Young AM, Kiviat NB.

J Natl Cancer Inst. 2005 Feb 16;97(4):273-82.

PMID:
15713962
11.

Development of a multiplex MethyLight assay for the detection of DAPK1 and SOX1 methylation in epithelial ovarian cancer in a north Indian population.

Kaur M, Singh A, Singh K, Gupta S, Sachan M.

Genes Genet Syst. 2016 Nov 26;91(3):175-181. Epub 2016 Jul 25.

12.

Association between promoter methylation of DAPK gene and HNSCC: A meta-analysis.

Cai F, Xiao X, Niu X, Zhong Y.

PLoS One. 2017 Mar 1;12(3):e0173194. doi: 10.1371/journal.pone.0173194. eCollection 2017.

13.

Epigenetic inactivation of DAPK1, p14ARF, mir-34a and -34b/c in acute promyelocytic leukaemia.

Ng HY, Wan TS, So CC, Chim CS.

J Clin Pathol. 2014 Jul;67(7):626-31. doi: 10.1136/jclinpath-2014-202276. Epub 2014 May 7.

PMID:
24811488
14.

Clinical effect of DAPK promoter methylation in gastric cancer: A systematic meta-analysis.

Jia W, Yu T, Cao X, An Q, Yang H.

Medicine (Baltimore). 2016 Oct;95(43):e5040. Review.

15.

LINE-1 hypomethylation in blood and tissue samples as an epigenetic marker for cancer risk: a systematic review and meta-analysis.

Barchitta M, Quattrocchi A, Maugeri A, Vinciguerra M, Agodi A.

PLoS One. 2014 Oct 2;9(10):e109478. doi: 10.1371/journal.pone.0109478. eCollection 2014. Review.

16.

Quantification of DAPK1 promoter methylation in bone marrow and peripheral blood as a follicular lymphoma biomarker.

Giachelia M, Bozzoli V, D'Alò F, Tisi MC, Massini G, Maiolo E, Guidi F, Cupelli E, Martini M, Larocca LM, Voso MT, Leone G, Hohaus S.

J Mol Diagn. 2014 Jul;16(4):467-76. doi: 10.1016/j.jmoldx.2014.03.003. Epub 2014 May 9.

PMID:
24814955
17.

Hypermethylation of DAPK1 is an independent prognostic factor predicting survival in diffuse large B-cell lymphoma.

Kristensen LS, Asmar F, Dimopoulos K, Nygaard MK, Aslan D, Hansen JW, Ralfkiaer E, Grønbæk K.

Oncotarget. 2014 Oct 30;5(20):9798-810.

18.

Population-based case-control study on DAPK1, RAR-β2 and MGMT methylation in liquid-based cytology.

Sun LL, Cao DY, Yang JX, Li H, Zhou XR, Song ZQ, Cheng XM, Chen J, Shen K.

Arch Gynecol Obstet. 2012 May;285(5):1433-9. doi: 10.1007/s00404-011-2149-6. Epub 2011 Nov 25.

PMID:
22116316
19.

Epigenetic alterations by methylation of RASSF1A and DAPK1 promoter sequences in mammary carcinoma detected in extracellular tumor DNA.

Ahmed IA, Pusch CM, Hamed T, Rashad H, Idris A, El-Fadle AA, Blin N.

Cancer Genet Cytogenet. 2010 Jun;199(2):96-100. doi: 10.1016/j.cancergencyto.2010.02.007.

PMID:
20471512
20.

The prognostic value of DAPK1 hypermethylation in gliomas: A site-specific analysis.

Li X, Pu J, Liu J, Chen Y, Li Y, Hou P, Shi B, Yang Q.

Pathol Res Pract. 2018 Jul;214(7):940-948. doi: 10.1016/j.prp.2018.05.023. Epub 2018 May 22.

PMID:
29807777

Supplemental Content

Support Center